Fox Chase Cancer Center and Arima Genomics, Inc. have formed a pioneering partnership to enhance cancer diagnostics through the use of three-dimensional DNA structure analysis. This collaboration aims to integrate advanced techniques into standard clinical practices, moving beyond traditional genetic testing methods. By focusing on how DNA folds and interacts within cells, this approach seeks to uncover genomic alterations often overlooked by standard sequencing.
At the heart of this initiative is the Cancer Epigenetics Institute at Fox Chase, which will incorporate Arima’s Hi-C-based technology into its diagnostic workflows for lymphoma and sarcoma. The institute plans to utilize Arima’s Aventa Lymphoma and Aventa FusionPlus tests, designed to detect intricate gene fusions and rearrangements linked to cancer progression.
Transforming Cancer Diagnosis and Treatment
Johnathan Whetstine, director of the Cancer Epigenetics Institute, emphasized the significance of this collaboration, describing it as a “true bench-to-bedside translation of discovery.” He noted that the partnership has evolved from years of foundational research into practical clinical application, potentially redefining how genomic organization informs diagnosis and treatment strategies.
Unlike conventional DNA sequencing, which often fragments genetic material and loses spatial context, Arima’s platform maintains the three-dimensional architecture of the genome. This broader perspective offers deeper insights into tumor formation, evolution, and treatment resistance. Clinical studies have shown that Arima’s Aventa tests effectively identify critical gene fusions and rearrangements, particularly in lymphomas and sarcomas.
Tom Willis, chief executive officer of Arima Genomics, highlighted the importance of this technology, stating that it provides “the most sensitive detection for gene fusions and rearrangements.” He views Fox Chase’s decision to implement this technology across multiple tumor types as a major advancement in cancer care.
Clinical Implementation and Future Research
With this partnership, Fox Chase becomes the first institution globally to adopt Arima’s 3D genomics testing as a routine protocol. The integration will involve collecting de-identified patient response data alongside clinical applications, which will offer researchers new opportunities to identify patterns that could lead to innovative therapies.
“This technology allows us to see not just what genetic changes occur, but how the DNA itself is organized,” Whetstine explained. He added that this information could help reveal new therapeutic targets or confirm findings with increased precision.
Peter Abdelmessieh, assistant professor at Fox Chase’s Blood Cancer and Cellular Therapy Institute, stressed the potential of this technology in challenging blood cancers. He remarked that while there have been significant advances in lymphoma treatments, relapses remain common. Access to Arima’s tools could significantly enhance diagnostic accuracy and treatment decisions for patients.
The partnership builds on a longstanding scientific relationship between Arima and the Cancer Epigenetics Institute, encompassing years of collaborative research and joint participation in symposiums. Both organizations view this partnership as a new frontier for cancer diagnostics, promising to transform the landscape of cancer care and research.
